EMEA (Europe, Middle East and Africa) Vaccine Conjugate Market Report 2017

October 2017 | 105 pages | ID: EE2E4E5A99FPEN
QYResearch

Abstracts

In this report, the EMEA Vaccine Conjugate market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report split EMEA into Europe, the Middle East and Africa, With sales (K MT), revenue (Million USD), market share and growth rate of Vaccine Conjugate for these regions, from 2012 to 2022 (forecast)

• Europe: Germany, France, UK, Russia, Italy and Benelux;
• Middle East: Saudi Arabia, Israel, UAE and Iran;
• Africa: South Africa, Nigeria, Egypt and Algeria.

EMEA Vaccine Conjugate market competition by top manufacturers/players, with Vaccine Conjugate sales volume (K MT), price (USD/MT), revenue (Million USD) and market share for each manufacturer/player; the top players including

• Merck & Co., Inc.
• GlaxoSmithKline plc.
• SutroVax Inc.
• Fablife.
• Pfizer
• Sinovac Biotech Ltd.
• Sanofi Pasteur SA.

On the basis of product, this report displays the sales volume (K MT), revenue (Million USD), product price (USD/MT), market share and growth rate of each type, primarily split into

• Monovalent
• Multivalent
• Others

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume (K MT), market share and growth rate of Vaccine Conjugate for each application, including

• Influenza
• Meningococcal
• Pneumococcal
• Others

If you have any special requirements, please let us know and we will offer you the report as you want.

Contents

EMEA (Europe, Middle East and Africa) Vaccine Conjugate Market Report 2017

1 VACCINE CONJUGATE OVERVIEW

1.1 Product Overview and Scope of Vaccine Conjugate
1.2 Classification of Vaccine Conjugate
  1.2.1 EMEA Vaccine Conjugate Market Size (Sales) Comparison by Type (2012-2022)
  1.2.2 EMEA Vaccine Conjugate Market Size (Sales) Market Share by Type (Product Category) in 2016
  1.2.3 Monovalent
  1.2.4 Multivalent
  1.2.5 Others
1.3 EMEA Vaccine Conjugate Market by Application/End Users
  1.3.1 EMEA Vaccine Conjugate Sales (Volume) and Market Share Comparison by Application (2012-2022
  1.3.2 Influenza
  1.3.3 Meningococcal
  1.3.4 Pneumococcal
  1.3.5 Others
1.4 EMEA Vaccine Conjugate Market by Region
  1.4.1 EMEA Vaccine Conjugate Market Size (Value) Comparison by Region (2012-2022)
  1.4.2 Europe Status and Prospect (2012-2022)
  1.4.3 Middle East Status and Prospect (2012-2022)
  1.4.4 Africa Status and Prospect (2012-2022)
1.5 EMEA Market Size (Value and Volume) of Vaccine Conjugate (2012-2022)
  1.5.1 EMEA Vaccine Conjugate Sales and Growth Rate (2012-2022)
  1.5.2 EMEA Vaccine Conjugate Revenue and Growth Rate (2012-2022)

2 EMEA VACCINE CONJUGATE COMPETITION BY MANUFACTURERS/PLAYERS/SUPPLIERS, REGION, TYPE AND APPLICATION

2.1 EMEA Vaccine Conjugate Market Competition by Players/Manufacturers
  2.1.1 EMEA Vaccine Conjugate Sales Volume and Market Share of Major Players (2012-2017)
  2.1.2 EMEA Vaccine Conjugate Revenue and Share by Players (2012-2017)
  2.1.3 EMEA Vaccine Conjugate Sale Price by Players (2012-2017)
2.2 EMEA Vaccine Conjugate (Volume and Value) by Type/Product Category
  2.2.1 EMEA Vaccine Conjugate Sales and Market Share by Type (2012-2017)
  2.2.2 EMEA Vaccine Conjugate Revenue and Market Share by Type (2012-2017)
  2.2.3 EMEA Vaccine Conjugate Sale Price by Type (2012-2017)
2.3 EMEA Vaccine Conjugate (Volume) by Application
2.4 EMEA Vaccine Conjugate (Volume and Value) by Region
  2.4.1 EMEA Vaccine Conjugate Sales and Market Share by Region (2012-2017)
  2.4.2 EMEA Vaccine Conjugate Revenue and Market Share by Region (2012-2017)
  2.4.3 EMEA Vaccine Conjugate Sales Price by Region (2012-2017)

3 EUROPE VACCINE CONJUGATE (VOLUME, VALUE AND SALES PRICE), BY PLAYERS, COUNTRIES, TYPE AND APPLICATION

3.1 Europe Vaccine Conjugate Sales and Value (2012-2017)
  3.1.1 Europe Vaccine Conjugate Sales Volume and Growth Rate (2012-2017)
  3.1.2 Europe Vaccine Conjugate Revenue and Growth Rate (2012-2017)
3.2 Europe Vaccine Conjugate Sales and Market Share by Type
3.3 Europe Vaccine Conjugate Sales and Market Share by Application
3.4 Europe Vaccine Conjugate Sales Volume and Value (Revenue) by Countries
  3.4.1 Europe Vaccine Conjugate Sales Volume by Countries (2012-2017)
  3.4.2 Europe Vaccine Conjugate Revenue by Countries (2012-2017)
  3.4.3 Germany Vaccine Conjugate Sales and Growth Rate (2012-2017)
  3.4.4 France Vaccine Conjugate Sales and Growth Rate (2012-2017)
  3.4.5 UK Vaccine Conjugate Sales and Growth Rate (2012-2017)
  3.4.6 Russia Vaccine Conjugate Sales and Growth Rate (2012-2017)
  3.4.7 Italy Vaccine Conjugate Sales and Growth Rate (2012-2017)
  3.4.8 Benelux Vaccine Conjugate Sales and Growth Rate (2012-2017)

4 MIDDLE EAST VACCINE CONJUGATE (VOLUME, VALUE AND SALES PRICE), BY REGION, TYPE AND APPLICATION

4.1 Middle East Vaccine Conjugate Sales and Value (2012-2017)
  4.1.1 Middle East Vaccine Conjugate Sales Volume and Growth Rate (2012-2017)
  4.1.2 Middle East Vaccine Conjugate Revenue and Growth Rate (2012-2017)
4.2 Middle East Vaccine Conjugate Sales and Market Share by Type
4.3 Middle East Vaccine Conjugate Sales and Market Share by Application
4.4 Middle East Vaccine Conjugate Sales Volume and Value (Revenue) by Countries
  4.4.1 Middle East Vaccine Conjugate Sales Volume by Countries (2012-2017)
  4.4.2 Middle East Vaccine Conjugate Revenue by Countries (2012-2017)
  4.4.3 Saudi Arabia Vaccine Conjugate Sales and Growth Rate (2012-2017)
  4.4.4 Israel Vaccine Conjugate Sales and Growth Rate (2012-2017)
  4.4.5 UAE Vaccine Conjugate Sales and Growth Rate (2012-2017)
  4.4.6 Iran Vaccine Conjugate Sales and Growth Rate (2012-2017)

5 AFRICA VACCINE CONJUGATE (VOLUME, VALUE AND SALES PRICE) BY PLAYERS, COUNTRIES, TYPE AND APPLICATION

5.1 Africa Vaccine Conjugate Sales and Value (2012-2017)
  5.1.1 Africa Vaccine Conjugate Sales Volume and Growth Rate (2012-2017)
  5.1.2 Africa Vaccine Conjugate Revenue and Growth Rate (2012-2017)
5.2 Africa Vaccine Conjugate Sales and Market Share by Type
5.3 Africa Vaccine Conjugate Sales and Market Share by Application
5.4 Africa Vaccine Conjugate Sales Volume and Value (Revenue) by Countries
  5.4.1 Africa Vaccine Conjugate Sales Volume by Countries (2012-2017)
  5.4.2 Africa Vaccine Conjugate Revenue by Countries (2012-2017)
  5.4.3 South Africa Vaccine Conjugate Sales and Growth Rate (2012-2017)
  5.4.4 Nigeria Vaccine Conjugate Sales and Growth Rate (2012-2017)
  5.4.5 Egypt Vaccine Conjugate Sales and Growth Rate (2012-2017)
  5.4.6 Algeria Vaccine Conjugate Sales and Growth Rate (2012-2017)

6 EMEA VACCINE CONJUGATE MANUFACTURERS/PLAYERS PROFILES AND SALES DATA

6.1 Merck & Co., Inc.
  6.1.1 Company Basic Information, Manufacturing Base and Competitors
  6.1.2 Vaccine Conjugate Product Type, Application and Specification
    6.1.2.1 Product A
    6.1.2.2 Product B
  6.1.3 Merck & Co., Inc. Vaccine Conjugate Sales, Revenue, Price and Gross Margin (2012-2017)
  6.1.4 Main Business/Business Overview
6.2 GlaxoSmithKline plc.
  6.2.1 Company Basic Information, Manufacturing Base and Competitors
  6.2.2 Vaccine Conjugate Product Type, Application and Specification
    6.2.2.1 Product A
    6.2.2.2 Product B
  6.2.3 GlaxoSmithKline plc. Vaccine Conjugate Sales, Revenue, Price and Gross Margin (2012-2017)
  6.2.4 Main Business/Business Overview
6.3 SutroVax Inc.
  6.3.1 Company Basic Information, Manufacturing Base and Competitors
  6.3.2 Vaccine Conjugate Product Type, Application and Specification
    6.3.2.1 Product A
    6.3.2.2 Product B
  6.3.3 SutroVax Inc. Vaccine Conjugate Sales, Revenue, Price and Gross Margin (2012-2017)
  6.3.4 Main Business/Business Overview
6.4 Fablife.
  6.4.1 Company Basic Information, Manufacturing Base and Competitors
  6.4.2 Vaccine Conjugate Product Type, Application and Specification
    6.4.2.1 Product A
    6.4.2.2 Product B
  6.4.3 Fablife. Vaccine Conjugate Sales, Revenue, Price and Gross Margin (2012-2017)
  6.4.4 Main Business/Business Overview
6.5 Pfizer
  6.5.1 Company Basic Information, Manufacturing Base and Competitors
  6.5.2 Vaccine Conjugate Product Type, Application and Specification
    6.5.2.1 Product A
    6.5.2.2 Product B
  6.5.3 Pfizer Vaccine Conjugate Sales, Revenue, Price and Gross Margin (2012-2017)
  6.5.4 Main Business/Business Overview
6.6 Sinovac Biotech Ltd.
  6.6.1 Company Basic Information, Manufacturing Base and Competitors
  6.6.2 Vaccine Conjugate Product Type, Application and Specification
    6.6.2.1 Product A
    6.6.2.2 Product B
  6.6.3 Sinovac Biotech Ltd. Vaccine Conjugate Sales, Revenue, Price and Gross Margin (2012-2017)
  6.6.4 Main Business/Business Overview
6.7 Sanofi Pasteur SA.
  6.7.1 Company Basic Information, Manufacturing Base and Competitors
  6.7.2 Vaccine Conjugate Product Type, Application and Specification
    6.7.2.1 Product A
    6.7.2.2 Product B
  6.7.3 Sanofi Pasteur SA. Vaccine Conjugate Sales, Revenue, Price and Gross Margin (2012-2017)
  6.7.4 Main Business/Business Overview

7 VACCINE CONJUGATE MANUFACTURING COST ANALYSIS

7.1 Vaccine Conjugate Key Raw Materials Analysis
  7.1.1 Key Raw Materials
  7.1.2 Price Trend of Key Raw Materials
  7.1.3 Key Suppliers of Raw Materials
  7.1.4 Market Concentration Rate of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
  7.2.1 Raw Materials
  7.2.2 Labor Cost
  7.2.3 Manufacturing Expenses
7.3 Manufacturing Process Analysis of Vaccine Conjugate

8 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS

8.1 Vaccine Conjugate Industrial Chain Analysis
8.2 Upstream Raw Materials Sourcing
8.3 Raw Materials Sources of Vaccine Conjugate Major Manufacturers in 2016
8.4 Downstream Buyers

9 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS

9.1 Marketing Channel
  9.1.1 Direct Marketing
  9.1.2 Indirect Marketing
  9.1.3 Marketing Channel Development Trend
9.2 Market Positioning
  9.2.1 Pricing Strategy
  9.2.2 Brand Strategy
  9.2.3 Target Client
9.3 Distributors/Traders List

10 MARKET EFFECT FACTORS ANALYSIS

10.1 Technology Progress/Risk
  10.1.1 Substitutes Threat
  10.1.2 Technology Progress in Related Industry
10.2 Consumer Needs/Customer Preference Change
10.3 Economic/Political Environmental Change

11 EMEA VACCINE CONJUGATE MARKET FORECAST (2017-2022)

11.1 EMEA Vaccine Conjugate Sales, Revenue and Price Forecast (2017-2022)
  11.1.1 EMEA Vaccine Conjugate Sales and Growth Rate Forecast (2017-2022)
  11.1.2 EMEA Vaccine Conjugate Revenue and Growth Rate Forecast (2017-2022)
  11.1.3 EMEA Vaccine Conjugate Price and Trend Forecast (2017-2022)
11.2 EMEA Vaccine Conjugate Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
11.3 Europe Vaccine Conjugate Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
11.4 Middle Eastt Vaccine Conjugate Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
11.5 Africa Vaccine Conjugate Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
11.6 EMEA Vaccine Conjugate Sales Forecast by Type (2017-2022)
11.7 EMEA Vaccine Conjugate Sales Forecast by Application (2017-2022)

12 RESEARCH FINDINGS AND CONCLUSION

13 APPENDIX

13.1 Methodology/Research Approach
  13.1.1 Research Programs/Design
  13.1.2 Market Size Estimation
  13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
  13.2.1 Secondary Sources
  13.2.2 Primary Sources
13.3 Disclaimer


The report requires updating with new data and is sent in 2-3 business days after order is placed.

List Of Tables

LIST OF TABLES AND FIGURES

Figure Product Picture of Vaccine Conjugate
Figure EMEA Vaccine Conjugate Sales Volume (K MT) by Type (2012-2022)
Figure EMEA Vaccine Conjugate Sales Volume Market Share by Type (Product Category) in 2016
Figure Monovalent Product Picture
Figure Multivalent Product Picture
Figure Others Product Picture
Figure EMEA Vaccine Conjugate Sales Volume (K MT) by Application (2012-2022)
Figure EMEA Sales Market Share of Vaccine Conjugate by Application in 2016
Figure Influenza Examples
Table Key Downstream Customer in Influenza
Figure Meningococcal Examples
Table Key Downstream Customer in Meningococcal
Figure Pneumococcal Examples
Table Key Downstream Customer in Pneumococcal
Figure Others Examples
Table Key Downstream Customer in Others
Figure EMEA Vaccine Conjugate Market Size (Million USD) by Region (2012-2022)
Figure Europe Vaccine Conjugate Revenue (Million USD) and Growth Rate (2012-2022)
Figure Europe Vaccine Conjugate Revenue (Million USD) Status and Forecast by Countries
Figure Middle East Vaccine Conjugate Revenue (Million USD) and Growth Rate (2012-2022)
Figure Middle East Vaccine Conjugate Revenue (Million USD) Status and Forecast by Countries
Figure Africa Vaccine Conjugate Revenue (Million USD) and Growth Rate (2012-2022)
Figure Africa Vaccine Conjugate Revenue (Million USD) Status and Forecast by Countries
Figure EMEA Vaccine Conjugate Sales Volume and Growth Rate (2012-2022)
Figure EMEA Vaccine Conjugate Revenue (Million USD) and Growth Rate (2012-2022)
Figure EMEA Vaccine Conjugate Market Major Players Product Sales Volume (K MT) (2012-2017)
Table EMEA Vaccine Conjugate Sales Volume (K MT) of Major Players (2012-2017)
Table EMEA Vaccine Conjugate Sales Share by Players (2012-2017)
Figure 2016 Vaccine Conjugate Sales Share by Players
Figure 2017 Vaccine Conjugate Sales Share by Players
Figure EMEA Vaccine Conjugate Market Major Players Product Revenue (Million USD) (2012-2017)
Table EMEA Vaccine Conjugate Revenue (Million USD) by Players (2012-2017)
Table EMEA Vaccine Conjugate Revenue Share by Players (2012-2017)
Table 2016 EMEA Vaccine Conjugate Revenue Share by Players
Table 2017 EMEA Vaccine Conjugate Revenue Share by Players
Table EMEA Vaccine Conjugate Sale Price (USD/MT) by Players (2012-2017)
Table EMEA Vaccine Conjugate Sales (K MT) and Market Share by Type (2012-2017)
Table EMEA Vaccine Conjugate Sales Share by Type (2012-2017)
Figure Sales Market Share of Vaccine Conjugate by Type (2012-2017)
Figure EMEA Vaccine Conjugate Sales Market Share by Type (2012-2017)
Table EMEA Vaccine Conjugate Revenue (Million USD) and Market Share by Type (2012-2017)
Table EMEA Vaccine Conjugate Revenue Share by Type (2012-2017)
Figure Revenue Market Share of Vaccine Conjugate by Type in 2016
Table EMEA Vaccine Conjugate Sale Price (USD/MT) by Type (2012-2017)
Table EMEA Vaccine Conjugate Sales (K MT) and Market Share by Application (2012-2017)
Table EMEA Vaccine Conjugate Sales Share by Application (2012-2017)
Figure Sales Market Share of Vaccine Conjugate by Application (2012-2017)
Figure EMEA Vaccine Conjugate Sales Market Share by Application in 2016
Table EMEA Vaccine Conjugate Sales (K MT) and Market Share by Region (2012-2017)
Table EMEA Vaccine Conjugate Sales Share by Region (2012-2017)
Figure Sales Market Share of Vaccine Conjugate by Region (2012-2017)
Figure EMEA Vaccine Conjugate Sales Market Share in 2016
Table EMEA Vaccine Conjugate Revenue (Million USD) and Market Share by Region (2012-2017)
Table EMEA Vaccine Conjugate Revenue Share by Region (2012-2017)
Figure Revenue Market Share of Vaccine Conjugate by Region (2012-2017)
Figure EMEA Vaccine Conjugate Revenue Market Share Regions in 2016
Table EMEA Vaccine Conjugate Sales Price (USD/MT) by Region (2012-2017)
Figure Europe Vaccine Conjugate Sales (K MT) and Growth Rate (2012-2017)
Figure Europe Vaccine Conjugate Revenue and Growth Rate (2012-2017)
Table Europe Vaccine Conjugate Sales (K MT) by Type (2012-2017)
Table Europe Vaccine Conjugate Market Share by Type (2012-2017)
Figure Europe Vaccine Conjugate Market Share by Type in 2016
Table Europe Vaccine Conjugate Sales (K MT) by Application (2012-2017)
Table Europe Vaccine Conjugate Market Share by Application (2012-2017)
Figure Europe Vaccine Conjugate Market Share by Application in 2016
Table Europe Vaccine Conjugate Sales (K MT) by Countries (2012-2017)
Table Europe Vaccine Conjugate Sales Market Share by Countries (2012-2017)
Figure Europe Vaccine Conjugate Sales Market Share by Countries (2012-2017)
Figure Europe Vaccine Conjugate Sales Market Share by Countries in 2016
Table Europe Vaccine Conjugate Revenue (Million USD) by Countries (2012-2017)
Table Europe Vaccine Conjugate Revenue Market Share by Countries (2012-2017)
Figure Europe Vaccine Conjugate Revenue Market Share by Countries (2012-2017)
Figure Europe Vaccine Conjugate Revenue Market Share by Countries in 2016
Figure Germany Vaccine Conjugate Sales (K MT) and Growth Rate (2012-2017)
Figure France Vaccine Conjugate Sales (K MT) and Growth Rate (2012-2017)
Figure UK Vaccine Conjugate Sales (K MT) and Growth Rate (2012-2017)
Figure Russia Vaccine Conjugate Sales (K MT) and Growth Rate (2012-2017)
Figure Italy Vaccine Conjugate Sales (K MT) and Growth Rate (2012-2017)
Figure Benelux Vaccine Conjugate Sales (K MT) and Growth Rate (2012-2017)
Figure Middle East Vaccine Conjugate Sales (K MT) and Growth Rate (2012-2017)
Figure Middle East Vaccine Conjugate Revenue (Million USD) and Growth Rate (2012-2017)
Table Middle East Vaccine Conjugate Sales (K MT) by Type (2012-2017)
Table Middle East Vaccine Conjugate Market Share by Type (2012-2017)
Figure Middle East Vaccine Conjugate Market Share by Type (2012-2017)
Table Middle East Vaccine Conjugate Sales (K MT) by Applications (2012-2017)
Table Middle East Vaccine Conjugate Market Share by Applications (2012-2017)
Figure Middle East Vaccine Conjugate Sales Market Share by Application in 2016
Table Middle East Vaccine Conjugate Sales Volume (K MT) by Countries (2012-2017)
Table Middle East Vaccine Conjugate Sales Volume Market Share by Countries (2012-2017)
Figure Middle East Vaccine Conjugate Sales Volume Market Share by Countries in 2016
Table Middle East Vaccine Conjugate Revenue (Million USD) by Countries (2012-2017)
Table Middle East Vaccine Conjugate Revenue Market Share by Countries (2012-2017)
Figure Middle East Vaccine Conjugate Revenue Market Share by Countries (2012-2017)
Figure Middle East Vaccine Conjugate Revenue Market Share by Countries in 2016
Figure Saudi Arabia Vaccine Conjugate Sales (K MT) and Growth Rate (2012-2017)
Figure Israel Vaccine Conjugate Sales (K MT) and Growth Rate (2012-2017)
Figure UAE Vaccine Conjugate Sales (K MT) and Growth Rate (2012-2017)
Figure Iran Vaccine Conjugate Sales (K MT) and Growth Rate (2012-2017)
Figure Africa Vaccine Conjugate Sales (K MT) and Growth Rate (2012-2017)
Figure Africa Vaccine Conjugate Revenue (Million USD) and Growth Rate (2012-2017)
Table Africa Vaccine Conjugate Sales (K MT) by Type (2012-2017)
Table Africa Vaccine Conjugate Sales Market Share by Type (2012-2017)
Figure Africa Vaccine Conjugate Sales Market Share by Type (2012-2017)
Figure Africa Vaccine Conjugate Sales Market Share by Type in 2016
Table Africa Vaccine Conjugate Sales (K MT) by Application (2012-2017)
Table Africa Vaccine Conjugate Sales Market Share by Application (2012-2017)
Figure Africa Vaccine Conjugate Sales Market Share by Application (2012-2017)
Table Africa Vaccine Conjugate Sales Volume (K MT) by Countries (2012-2017)
Table Africa Vaccine Conjugate Sales Market Share by Countries (2012-2017)
Figure Africa Vaccine Conjugate Sales Market Share by Countries (2012-2017)
Figure Africa Vaccine Conjugate Sales Market Share by Countries in 2016
Table Africa Vaccine Conjugate Revenue (Million USD) by Countries (2012-2017)
Table Africa Vaccine Conjugate Revenue Market Share by Countries (2012-2017)
Figure Africa Vaccine Conjugate Revenue Market Share by Countries (2012-2017)
Figure Africa Vaccine Conjugate Revenue Market Share by Countries in 2016
Figure South Africa Vaccine Conjugate Sales (K MT) and Growth Rate (2012-2017)
Figure Nigeria Vaccine Conjugate Sales (K MT) and Growth Rate (2012-2017)
Figure Egypt Vaccine Conjugate Sales (K MT) and Growth Rate (2012-2017)
Figure Algeria Vaccine Conjugate Sales (K MT) and Growth Rate (2012-2017)
Table Merck & Co., Inc. Vaccine Conjugate Basic Information List
Table Merck & Co., Inc. Vaccine Conjugate Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2012-2017)
Figure Merck & Co., Inc. Vaccine Conjugate Sales (K MT) and Growth Rate (2012-2017)
Figure Merck & Co., Inc. Vaccine Conjugate Sales Market Share in EMEA (2012-2017)
Figure Merck & Co., Inc. Vaccine Conjugate Revenue Market Share in EMEA (2012-2017)
Table GlaxoSmithKline plc. Vaccine Conjugate Basic Information List
Table GlaxoSmithKline plc. Vaccine Conjugate Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2012-2017)
Figure GlaxoSmithKline plc. Vaccine Conjugate Sales (K MT) and Growth Rate (2012-2017)
Figure GlaxoSmithKline plc. Vaccine Conjugate Sales Market Share in EMEA (2012-2017)
Figure GlaxoSmithKline plc. Vaccine Conjugate Revenue Market Share in EMEA (2012-2017)
Table SutroVax Inc. Vaccine Conjugate Basic Information List
Table SutroVax Inc. Vaccine Conjugate Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2012-2017)
Figure SutroVax Inc. Vaccine Conjugate Sales (K MT) and Growth Rate (2012-2017)
Figure SutroVax Inc. Vaccine Conjugate Sales Market Share in EMEA (2012-2017)
Figure SutroVax Inc. Vaccine Conjugate Revenue Market Share in EMEA (2012-2017)
Table Fablife. Vaccine Conjugate Basic Information List
Table Fablife. Vaccine Conjugate Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2012-2017)
Figure Fablife. Vaccine Conjugate Sales (K MT) and Growth Rate (2012-2017)
Figure Fablife. Vaccine Conjugate Sales Market Share in EMEA (2012-2017)
Figure Fablife. Vaccine Conjugate Revenue Market Share in EMEA (2012-2017)
Table Pfizer Vaccine Conjugate Basic Information List
Table Pfizer Vaccine Conjugate Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2012-2017)
Figure Pfizer Vaccine Conjugate Sales (K MT) and Growth Rate (2012-2017)
Figure Pfizer Vaccine Conjugate Sales Market Share in EMEA (2012-2017)
Figure Pfizer Vaccine Conjugate Revenue Market Share in EMEA (2012-2017)
Table Sinovac Biotech Ltd. Vaccine Conjugate Basic Information List
Table Sinovac Biotech Ltd. Vaccine Conjugate Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2012-2017)
Figure Sinovac Biotech Ltd. Vaccine Conjugate Sales (K MT) and Growth Rate (2012-2017)
Figure Sinovac Biotech Ltd. Vaccine Conjugate Sales Market Share in EMEA (2012-2017)
Figure Sinovac Biotech Ltd. Vaccine Conjugate Revenue Market Share in EMEA (2012-2017)
Table Sanofi Pasteur SA. Vaccine Conjugate Basic Information List
Table Sanofi Pasteur SA. Vaccine Conjugate Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2012-2017)
Figure Sanofi Pasteur SA. Vaccine Conjugate Sales (K MT) and Growth Rate (2012-2017)
Figure Sanofi Pasteur SA. Vaccine Conjugate Sales Market Share in EMEA (2012-2017)
Figure Sanofi Pasteur SA. Vaccine Conjugate Revenue Market Share in EMEA (2012-2017)
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Vaccine Conjugate
Figure Manufacturing Process Analysis of Vaccine Conjugate
Figure Vaccine Conjugate Industrial Chain Analysis
Table Raw Materials Sources of Vaccine Conjugate Major Manufacturers in 2016
Table Major Buyers of Vaccine Conjugate
Table Distributors/Traders List
Figure EMEA Vaccine Conjugate Sales (K MT) and Growth Rate Forecast (2017-2022)
Figure EMEA Vaccine Conjugate Revenue and Growth Rate Forecast (2017-2022)
Figure EMEA Vaccine Conjugate Price (USD/MT) and Trend Forecast (2017-2022)
Table EMEA Vaccine Conjugate Sales (K MT) Forecast by Region (2017-2022)
Figure EMEA Vaccine Conjugate Sales Market Share Forecast by Region (2017-2022)
Table EMEA Vaccine Conjugate Revenue (Million USD) Forecast by Region (2017-2022)
Figure EMEA Vaccine Conjugate Revenue Market Share Forecast by Region (2017-2022)
Table Europe Vaccine Conjugate Sales (K MT) Forecast by Countries (2017-2022)
Figure Europe Vaccine Conjugate Sales Market Share Forecast by Countries (2017-2022)
Table Europe Vaccine Conjugate Revenue (Million USD) Forecast by Countries (2017-2022)
Figure Europe Vaccine Conjugate Revenue Market Share Forecast by Countries (2017-2022)
Table Middle East Vaccine Conjugate Sales (K MT) Forecast by Countries (2017-2022)
Figure Middle East Vaccine Conjugate Sales Market Share Forecast by Countries (2017-2022)
Table Middle East Vaccine Conjugate Revenue (Million USD) Forecast by Countries (2017-2022)
Figure Middle East Vaccine Conjugate Revenue Market Share Forecast by Countries (2017-2022)
Table Africa Vaccine Conjugate Sales (K MT) Forecast by Countries (2017-2022)
Figure Africa Vaccine Conjugate Sales Market Share Forecast by Countries (2017-2022)
Table Africa Vaccine Conjugate Revenue (Million USD) Forecast by Countries (2017-2022)
Figure Africa Vaccine Conjugate Revenue Market Share Forecast by Countries (2017-2022)
Table EMEA Vaccine Conjugate Sales (K MT) Forecast by Type (2017-2022)
Figure EMEA Vaccine Conjugate Sales Market Share Forecast by Type (2017-2022)
Table EMEA Vaccine Conjugate Sales (K MT) Forecast by Application (2017-2022)
Figure EMEA Vaccine Conjugate Sales Market Share Forecast by Application (2017-2022)
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources